Evidence map›Paper›PMID 36411524›Full record

ReviewCancer reports (Hoboken, N.J.)2022

Maternal obesity and resistance to breast cancer treatments among offspring: Link to gut dysbiosis.

Fabia de Oliveira Andrade, Vivek Verma, Leena Hilakivi-Clarke

Open access · goldAbstract readReview
In one paragraph

Review in Cancer reports (Hoboken, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Fabia de Oliveira AndradeThe Hormel Institute, University of Minnesota, Austin, Minnesota, USA.ORCID 0000-0003-0860-0847
Vivek VermaThe Hormel Institute, University of Minnesota, Austin, Minnesota, USA.ORCID 0000-0001-8129-4140
Leena Hilakivi-ClarkeThe Hormel Institute, University of Minnesota, Austin, Minnesota, USA.ORCID 0000-0002-7052-6513
University of Minnesota · US

Funding

Improving response to immunotherapy by genistein and antiestrogensR21CA256428 · NCI · UNIVERSITY OF MINNESOTA · PI HILAKIVI-CLARKE, LEENA A. · 2021 to 2021
$408k
NCI NIH HHS R21 CA256428
6 · The paper itself

Abstract

backgroundAbout 50 000 new cases of cancer in the United States are attributed to obesity. The adverse effects of obesity on breast cancer may be most profound when affecting the early development; that is, in the womb of a pregnant obese mother. Maternal obesity has several long-lasting adverse health effects on the offspring, including increasing offspring's breast cancer risk and mortality. Gut microbiota is a player in obesity as well as may impact breast carcinogenesis. Gut microbiota is established early in life and the microbial composition of an infant's gut becomes permanently dysregulated because of maternal obesity. Metabolites from the microbiota, especially short chain fatty acids (SCFAs), play a critical role in mediating the effect of gut bacteria on multiple biological functions, such as immune system, including tumor immune responses. RECENT

findingsMaternal obesity can pre-program daughter's breast cancer to be more aggressive, less responsive to treatments and consequently more likely to cause breast cancer related death. Maternal obesity may also induce poor response to immune checkpoint inhibitor (ICB) therapy through increased abundance of inflammation associated microbiome and decreased abundance of bacteria that are linked to production of SCFAs. Dietary interventions that increase the abundance of bacteria producing SCFAs potentially reverses offspring's resistance to breast cancer therapy.

conclusionSince immunotherapies have emerged as highly effective treatments for many cancers, albeit there is an urgent need to enlarge the patient population who will be responsive to these treatments. One of the factors which may cause ICB refractoriness could be maternal obesity, based on its effects on the microbiota markers of ICB therapy response among the offspring. Since about 40% of children are born to obese mothers in the Western societies, it is important to determine if maternal obesity impairs offspring's response to cancer immunotherapies.

Indexed as

Breast NeoplasmsGastrointestinal MicrobiomePregnancy in ObesityChildDysbiosisFemaleHumansInfantObesityPregnancygut microbiomeimmunotherapymaternal obesityoffspringshort chain fatty acids

Identifiers

PMID36411524
PMCPMC9780430
OpenAlexW4309656323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.